NICE is considering an evaluation of drisapersen for treating Duchenne muscular dystrophy.
The Institute has now been informed by the company that it has withdrawn its Marketing Authorisation for drisapersen in this indication, from the European Medicines Agency. Therefore, NICE has decided to suspend this evaluation on its current work programme.
As this topic has been referred to the Institute we will continue to monitor any development
| Status | Suspended |
| Decision | Selected |
| Process | HST |
| ID number | 911 |
Project Team
| Project lead | Leanne Wakefield |
Email enquiries
- If you have any queries please email HST@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 28 June 2016 | Suspended. NICE is considering an evaluation of drisapersen for treating Duchenne muscular dystrophy. The Institute has now been informed by the company that it has withdrawn its Marketing Authorisation for drisapersen in this indication, from the European Medicines Agency. Therefore, NICE has decided to suspend this evaluation on its current work programme. As this topic has been referred to the Institute we will continue to monitor any development |
| 28 June 2016 | Draft scope documents |
For further information on our processes and methods, please see our CHTE processes and methods manual